                </a></li></ul></div><p><strong>Figure 2.  <span>Rosiglitazone treatment decreases expression of PDGFRβ and activation of Smad2/3 (pSmad2/3) <em>in vitro</em>.</span></strong></p><a id="article1.body1.sec2.sec2.fig1.caption1.p1" name="article1.body1.sec2.sec2.fig1.caption1.p1"></a><p>Western blot analysis of activated Smad2/3 and PDGFRβ in whole cell lysates from human VSMC and MEF LRP<sup>+/+</sup> cells pretreated 0, 24 or 48 hours with rosiglitazone at 10<sup>−5</sup>M and then stimulated with human TGFβ1 (200&nbsp;pM) for 0, 1.5, 3 or 6 hours.</p>
